|Bid||2.2800 x 0|
|Ask||2.3200 x 0|
|Day's Range||2.2000 - 2.3800|
|52 Week Range||1.9800 - 6.6900|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.44|
IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company’s business and clinical operations amid the COVID-19 pandemic.
IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a core part of IMV’s heritage across its DPX platform technology.
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investing in stocks comes with the risk that the share price will fall. And there's no doubt that IMV Inc. (TSE:IMV...